These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23564377)

  • 1. Bevacizumab and central nervous system (CNS) hemorrhage.
    Letarte N; Bressler LR; Villano JL
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1561-5. PubMed ID: 23564377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab safety in patients with central nervous system metastases.
    Besse B; Lasserre SF; Compton P; Huang J; Augustus S; Rohr UP
    Clin Cancer Res; 2010 Jan; 16(1):269-78. PubMed ID: 20028762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis.
    Zuo PY; Chen XL; Liu YW; Xiao CL; Liu CY
    PLoS One; 2014; 9(7):e102484. PubMed ID: 25025282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracranial hemorrhage in patients treated with bevacizumab: report of two cases.
    Nishimura T; Furihata M; Kubo H; Tani M; Agawa S; Setoyama R; Toyoda T
    World J Gastroenterol; 2011 Oct; 17(39):4440-4. PubMed ID: 22110272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and tolerability of bevacizumab in children with primary CNS tumors.
    Reismüller B; Azizi AA; Peyrl A; Heinrich M; Gruber-Olipitz M; Luckner D; Rothschild KV; Slavc I
    Pediatr Blood Cancer; 2010 May; 54(5):681-6. PubMed ID: 20066713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Add-on-therapy with bevacizumab in children and adolescents with poor prognosis non-CNS solid tumors.
    Pansy J; Fritsch P; Sovinz P; Lackner H; Schwinger W; Urban C; Benesch M
    Anticancer Drugs; 2013 Feb; 24(2):198-203. PubMed ID: 23154263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC.
    Dansin E; Cinieri S; Garrido P; Griesinger F; Isla D; Koehler M; Kohlhaeufl M
    Lung Cancer; 2012 Jun; 76(3):373-9. PubMed ID: 22236866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
    Cohen MH; Shen YL; Keegan P; Pazdur R
    Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience.
    Khasraw M; Holodny A; Goldlust SA; DeAngelis LM
    Ann Oncol; 2012 Feb; 23(2):458-63. PubMed ID: 21543627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diaphragmatic rupture, a new complication of Bevacizumab.
    Lacaze L; Scotté M
    Eur J Surg Oncol; 2012 Nov; 38(11):1079-81. PubMed ID: 22818843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.
    Klamerus JF; Brahmer JR
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S51-6. PubMed ID: 21884999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases.
    Sandler A; Hirsh V; Reck M; von Pawel J; Akerley W; Johnson DH
    Lung Cancer; 2012 Oct; 78(1):1-7. PubMed ID: 22877947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case report-bleeding from the ulcer of wound for mastectomy after postoperative chemotherapy with bevacizumab for Sigmoid colon cancer].
    Tsumuraya M; Fujita M; Muroi H; Sugawara A; Tsubaki M; Kato H
    Gan To Kagaku Ryoho; 2011 Nov; 38(11):1869-71. PubMed ID: 22083200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.
    Socinski MA; Langer CJ; Huang JE; Kolb MM; Compton P; Wang L; Akerley W
    J Clin Oncol; 2009 Nov; 27(31):5255-61. PubMed ID: 19738122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.
    Kabbinavar FF; Flynn PJ; Kozloff M; Ashby MA; Sing A; Barr CE; Grothey A
    Eur J Cancer; 2012 May; 48(8):1126-32. PubMed ID: 22424880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.
    Tassinari D; Sartori S; Papi M; Drudi F; Castellani C; Carloni F; Tombesi P; Lazzari-Agli L
    Oncology; 2011; 80(5-6):350-8. PubMed ID: 21791945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haematologic toxicities associated with the addition of bevacizumab in cancer patients.
    Schutz FA; Jardim DL; Je Y; Choueiri TK
    Eur J Cancer; 2011 May; 47(8):1161-74. PubMed ID: 21470847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Feasibility of bevacizumab for elderly patients with metastatic colorectal cancer].
    Tsuchida K; Asari M; Numata K; Yoshida T; Osaragi T; Yoneyama K; Kasahara A; Yamamoto Y; Rino Y; Masuda M
    Gan To Kagaku Ryoho; 2012 Sep; 39(9):1379-83. PubMed ID: 22996773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.